

STEPHEN F. LYNCH

8TH DISTRICT, MASSACHUSETTS

COMMITTEE ON FINANCIAL SERVICES

SUBCOMMITTEE ON CAPITAL MARKETS AND

GOVERNMENT SPONSORED ENTERPRISES

SUBCOMMITTEE ON FINANCIAL INSTITUTIONS
AND CONSUMER CREDIT

COMMITTEE ON OVERSIGHT AND
GOVERNMENT REFORM

RANKING MEMBER, SUBCOMMITTEE ON
NATIONAL SECURITY

SUBCOMMITTEE ON GOVERNMENT OPERATIONS

ASSISTANT DEMOCRATIC WHIP

Congress of the United States

House of Representatives

Washington, DC 20515-2108

2369 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515

202-225-8273

202-225-3984 FAX

1 HARBOR STREET

SUITE 304

BOSTON, MA 02210

617-428-2000

617-428-2011 FAX

PLYMOUTH COUNTY REGISTRY BUILDING

155 WEST ELM STREET

SUITE 200

BROCKTON, MA 02301

508-586-5555

508-580-4692 FAX

1245 HANCOCK STREET

SUITE 16

QUINCY, MA 02169

617-657-6305

617-773-0995 FAX

LYNCH.HOUSE.GOV

September 1, 2016

The Honorable Jason Chaffetz
Chairman

Committee on Oversight and Government Reform

2157 Rayburn House Office Building

Washington, DC 20515

Dear Chairman Chaffetz:


I am writing to respectfully request that the Committee on Oversight and Government Reform convene a hearing on the dramatic increase in the price of the EpiPen auto-injector, manufactured by the drug maker Mylan. The EpiPen is used to administer the drug epinephrine, which treats life-threatening allergic reactions.

Recent reports in the press indicate that Mylan, which enjoys a virtual monopoly on epinephrine auto-injectors, has increased the retail price for a two-pack of the EpiPen from less than \$100 in 2007 to \$608.61. The price has climbed more than 550% since Mylan acquired the rights to sell the product in 2007, earning the company \$1 billion per year in sales and accounting for approximately 40% of its operating profits. And Mylan, through savvy marketing and the assistance of favorable government actions, has seen annual prescriptions of the EpiPen more than double in the last decade to 3.6 million. I do not begrudge a company its successes and profit, but such should not be earned by regularly increasing the cost of a life saving device on which so many Americans rely.

While Mylan announced recently that they will introduce a generic form of the EpiPen and CEO Heather Bresch has publicly committed to helping patients cope with the increased cost of the EpiPen by increasing the amount of money on their co-pay assistance card and expanding program eligibility, the company has not committed to lowering the price. Bresch has instead pointed to deficiencies in the healthcare system generally and specifically to "insurers, pharmacy benefit managers, and other middlemen" as reasons for the exorbitant cost. Yet Mylan retains nearly 50% percent, \$274, of the \$608.61 cost of each two-pack of the EpiPen. A hearing will afford the Committee the opportunity to conduct oversight of these and other issues affecting cost of and access to critical components of our healthcare system.

We are obligated to our constituents, many of whom rely on this critical device, to hold a hearing and question Mylan as to their justification for the steady and burdensome cost increase of the EpiPen. I look forward to working with you on this important concern.

Sincerely,



STEPHEN F. LYNCH
Member of Congress

Cc. Elijah E. Cummings, Ranking Member